Axovant Sciences is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics for the treatment of dementia in the United States and Europe. Its best known product, intepirdine, is a selective 5-HT6 receptor antagonist. It is currently in Phase III clinical trial for the treatment of Alzheimer's disease and in Phase II clinical trial for treating dementia. The company was formerly known as Roivant Neurosciences. Founded in 2014, it is based in Hamilton, Bermuda.